CLOs on the Move

Hemispherx Biopharma

www.hemispherx.net

 
Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Its products include Ampligen, which is under clinical development for the treatment of Chronic Fatigue Syndrome, Hepatitis B, human immunodeficiency virus (HIV), renal cell carcinoma, and malignant melanoma; Alferon N Injection, an injectable formulation of natural alpha interferon for the treatment of certain categories of genital warts; and Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of influenza and other emerging ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Orexigen

Orexigen`s commitment to patients is reflected in all that we do: we are a company driven by the knowledge that our work is important and the desire to make a difference. Orexigen offers prospective employees exciting challenges` unique opportunities for career growth` and a fast-paced environment that emphasizes innovation and achievement.

The loge Group

The loge Group LLC is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

CME

CME was founded in 1978 by psychiatrist John Schwartz, whose vision was to provide high-quality, practical continuing medical education and information for mental health clinicians throughout the United States. In its first decade, CME successfully

Orbus Therapeutics

Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.

Mantra Health

Mantra Health is a digital mental health clinic on a mission to improve young peoples` mental healthcare access through clinical services, software, and design. Since our founding in 2018, we`ve built a comprehensive treatment service for young adults with various mental health conditions. We`ve raised over $27 million to work with students at universities and colleges across the country such as MIT, Cornell, and the University of Minnesota. Our students see clinically significant differences in their mental health during treatment with us. We`re particularly proud that nearly two-thirds of students with access to Mantra report that Mantra`s program helped them stay in school.